Vendor comparison · 2026
Melanotan II vendors: 29 compared on COAs and price
DermatologicalAlso known as MT-2
Evidence tier
Some human data
5 observational
- Vendors carrying it
- 29
- 23 with a listed price
- Vendors with checkable COAs
- 13
- 14 publish any certificate
- Lots tested
- 18
- 17 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 17 Sept 2026
- oldest 20 Nov 2025
- Laboratories named
- 6
- most often Freedom Diagnostics Testing
- Median label gap
- 4.8%
- 56% of lots within 5% of label
- Median purity
- 99.81%
- 17 of 18 lots at 99% or above
- Lowest price per mg
- $2.50
- peer median $4.00
- Publications located
- 242
- researched since 1992
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Next Gen Peptides has the most checkable Melanotan II testing in this index: 3 lots assayed by ILS Laboratories, the newest on 18 Aug 2026. The lowest listed price is $2.50 per mg at Next Gen Peptides, the same vendor, against a peer median of $4.00. 29 vendors carrying Melanotan II are compared below. 13 publish at least one certificate naming a checkable laboratory, 18 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Melanotan II
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Origin LabsISO/IEC 17025 | 96.9100% | — | 1 / 1 | Freedom Diagnostics Testing | 99.7% | 4.1% | ||
| 2 | Next Gen PeptidesISO/IEC 17025 | 93.697% | $2.50 (63%) | 3 / 3 | ILS Laboratories | 99.9% | 5.5% | ||
| 3 | Amino ClubISO/IEC 17025Age-gated COAs | 90.598% | $3.00 (75%) | 2 / 2 | ILS Laboratories | 99.7% | 5.7% | ||
| 4 | Ascend ScienceISO/IEC 17025 | 88.994% | $3.50 (88%) | 0 | — | — | — | — | |
| 5 | One Aminos | 84.389% | $3.50 (88%) | 1 / 1 | United Laboratories | 99.5% | 2.6% | ||
| 6 | PeptidePlugs | 84.394% | $4.00 (100%) | 2 / 2 | Freedom Diagnostics Testing | 99.7% | 4.0% | ||
| 7 | Hydro Research PeptidesISO/IEC 17025 | 83.989% | — | 0 / 1 | Not named | 99.5% | 18.2% | ||
| 8 | Modern AminosISO/IEC 17025COAs need an account | 81.997% | $3.80 (95%) | 0 | — | — | — | — | no reportVisit site |
| 9 | Simple Peptide | 80.192% | $3.80 (95%) | 1 / 1 | Freedom Diagnostics Testing | 99.8% | 24.0% | ||
| 10 | NeuroLabs Research | 79.891% | $4.19 (105%) | 1 / 1 | Freedom Diagnostics Testing | 99.9% | 0.9% | ||
| 11 | Stealth Research Labs | 79.691% | $4.50 (113%) | 1 / 1 | Bioviridian Inc. | 99.9% | 4.4% | ||
| 12 | Bench Grade Peptides | 78.289% | $4.50 (113%) | 1 / 1 | AV Analytics | 99.8% | 0.9% | ||
| 13 | Protide HealthAge-gated COAs | 78.192% | $4.00 (100%) | 0 | — | — | — | — | no reportVisit site |
| 14 | Ascension Peptides | 76.489% | $5.00 (125%) | 0 | — | — | — | — | no reportVisit site |
| 15 | Prime PeptidesISO/IEC 17025 | 75.796% | $4.00 (100%) | 0 | — | — | — | — | no reportVisit site |
| 16 | Evo Labs Research | 72.387% | $4.00 (100%) | 0 | — | — | — | — | no reportVisit site |
| 17 | Northline LabsISO/IEC 17025 | 7195% | — | 1 / 1 | ILS Laboratories | 99.8% | 6.0% | ||
| 18 | Good Science Bio | 7071% | $3.50 (88%) | 0 | — | — | — | — | no reportVisit site |
| 19 | Eternal Peptides | 67.563% | $2.90 (73%) | 0 | — | — | — | — | no reportVisit site |
| 20 | GenX Peptides | 66.869% | $3.80 (95%) | 0 | — | — | — | — | no reportVisit site |
| 21 | Koi PeptidesAge-gated COAs | 66.492% | $6.00 (150%) | 0 | — | — | — | — | no reportVisit site |
| 22 | Extreme Peptides | 65.280% | $4.00 (100%) | 0 | — | — | — | — | no reportVisit site |
| 23 | True Research Labs | 64.568% | $3.90 (98%) | 0 | — | — | — | — | no reportVisit site |
| 24 | Licensed Peptides | 60.687% | $6.60 (165%) | 0 | — | — | — | — | no reportVisit site |
| 25 | Mile High Compounds | 60.591% | $4.00 (100%) | 0 | — | — | — | — | no reportVisit site |
| 26 | Vial Drop Labs | 59.474% | — | 1 / 1 | KMD Analytical (KMD Group LLC) | 98.7% | 0.9% | ||
| 27 | Improved Peptides | 59.187% | $5.60 (140%) | 0 | — | — | — | — | no reportVisit site |
| 28 | Vertex Labs | 56.172% | — | 1 / 1 | Freedom Diagnostics Testing | 99.8% | 7.0% | ||
| 29 | Peptime | 55.557% | — | 1 / 1 | Freedom Diagnostics Testing | 99.9% | 8.0% |
Independent assays
No independently commissioned assay of Melanotan II is on file. All 18 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
17 of 18 lots at 99% or above; median 99.81%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 1 |
| 99–99.5% | 1 |
| ≥99.5% | 16 |
56% of lots within 5% of the labelled mass; median gap 4.8%.
| Range | lots |
|---|---|
| ≤2% | 3 |
| 2–5% | 7 |
| 5–10% | 6 |
| 10–20% | 1 |
| >20% | 1 |
23 vendors, $2.50 to $6.60; median $4.00.
| Range | vendors |
|---|---|
| $2.00–$3.00 | 2 |
| $3.00–$4.00 | 8 |
| $4.00–$5.00 | 9 |
| $5.00–$6.00 | 2 |
| $6.00–$7.00 | 2 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| Freedom Diagnostics TestingUS | 7 | 6 | 39% | Public lookup |
| ILS LaboratoriesUS | 6 | 3 | 33% | Public lookup |
| AV Analytics | 1 | 1 | 6% | No public lookup found |
| Bioviridian Inc.US | 1 | 1 | 6% | Public lookup |
| KMD Analytical (KMD Group LLC)US | 1 | 1 | 6% | Public lookup |
| United LaboratoriesIN | 1 | 1 | 6% | Public lookup |
1 further record namesno checkable laboratory (a placeholder, a signature line or the vendor’s own name). It is listed in the certificate table but not counted as third-party testing.
Every certificate record
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1992 — 34 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
242 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.7% across 18 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.29 pts purity across lots, mean label deviation 6.3%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
29 of 29 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
17 of 18 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Melanotan II?
A synthetic analogue of alpha-melanocyte stimulating hormone. It has been the subject of regulatory warnings in several countries regarding unlicensed sale.
Studied in published research for skin tanning and sexual function.
Regulatory status
Not an approved medicine. Subject to regulatory warnings in several jurisdictions. Labeled by vendors for laboratory research use only.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Published work is limited and early-phase. Several national regulators have issued public warnings about products containing this compound sold outside a licensed medical context. PepIndex records the existence of those warnings as a matter of public record.
- Melanotan II: a possible cause of renal infarction: review of the literature and case report — CEN case reports (2020)
Peer-reviewed article indexed in PubMed, published in CEN case reports (2020).
- Melanotan-II reverses memory impairment induced by a short-term HF diet — Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2023)
Peer-reviewed article indexed in PubMed, published in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2023).
- Melanotan II User Experience: A Qualitative Study of Online Discussion Forums — Dermatology (Basel, Switzerland) (2021)
Peer-reviewed article indexed in PubMed, published in Dermatology (Basel, Switzerland) (2021).
- CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists — Journal of medicinal chemistry (2022)
Peer-reviewed article indexed in PubMed, published in Journal of medicinal chemistry (2022).
- Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism — PloS one (2019)
Peer-reviewed article indexed in PubMed, published in PloS one (2019).
- Discovery and development of novel melanogenic drugs. Melanotan-I and -II — Pharmaceutical biotechnology (1998)
Peer-reviewed article indexed in PubMed, published in Pharmaceutical biotechnology (1998).
- Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food — Neuropeptides (2022)
Peer-reviewed article indexed in PubMed, published in Neuropeptides (2022).
- Melanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice — Experimental physiology (2021)
Peer-reviewed article indexed in PubMed, published in Experimental physiology (2021).
Indexed studies5 human-evidence of 5
- Published reports concerning melanotan II obtained outside licensed supply — Case report
The listed literature includes case reports concerning material obtained outside a licensed medical context. Case reports describe individual occurrences and cannot establish incidence, causation or population-level risk.
- Melanotan-induced priapism: a hard-earned tan — Case report, 2019
Melanocortin analogues, such as melanotan, are illegally used for artificial tanning. They have also been suggested as possible therapeutic agents in the treatment of erectile dysfunction. This case study presents a patient attending the accident and emergency department, in a tertiary urology centre, with acute priapism after abdominal subcutaneous injection of melanotan. The priapism was diagnosed as 'low-flow' and managed with cavernosal aspiration, irrigation and subseque…
- Melanotan-associated melanoma — Case report, 2011
A case report published in The British journal of dermatology (2011). Reported outcomes are described in the linked publication; PepIndex does not summarise clinical significance.
- Melanotan II: a possible cause of renal infarction: review of the literature and case report — Case report, 2020
Renal infarction is an uncommon condition resulting from an acute disruption of renal blood flow and it is potentially life-threatening disease. The cause and outcome of renal infarction is not well established and is frequently misdiagnosed or diagnosed late. Melanotan II is a non-selective melanocortin-receptor agonist and its effect on humans is an increasing of skin pigmentation, producing of spontaneous penile erection and sexual stimulation. Melanotan II inducing rhabdo…
- A glimpse into the underground market of melanotan — Human — observational, 2018
Melanotan-I and melanotan-II are alpha-melanocyte stimulating hormone (a-MSH) analogues that can be purchased illicitly online with relative ease and are injected subcutaneously to stimulate a tan. Little is known about the use of these unregulated substances. An observational survey was posted to an online forum in which participants share their experiences using melanotan-I or melanotan-II. Users were asked to complete this voluntary, anonymous survey, which had questions f…
Evidence digest
What the research on Melanotan II actually shows
The indexed literature on Melanotan II includes human clinical or observational records (5 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Melanotan II is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.